drug development prodrug phd seminar mehdi akhlaghi
DESCRIPTION
Prodrug strategy , drug developmentTRANSCRIPT
1
Sharif University of Technology
Department of Chemistry
Ph.D. Seminar I
By: Mehdi Akhlaghi
Supervisor: Prof. Ali Pourjavadi
Kimia hall
Tuesday, June 21, 2011 (3:00 p.m.)
31 khordad 1390
Drug Discovery and Development: Prodrug Strategy to Increase
Success
2
How are drugs discovered and developed?How are drugs discovered and developed?
Prodrug strategy will increase success of process ?Prodrug strategy will increase success of process ?
Drug Discovery and Development
By: Mehdi Akhlaghi Supervisor: Dr. Pourjavadi
3
FDA Definition of a DrugAny chemical agent which effects any biological processAny chemical agent which effects any biological process“ “ An active ingredient that is intended to furnish pharmacological activity or An active ingredient that is intended to furnish pharmacological activity or
other direct effect in the diagnosis, cure, mitigation, treatment, or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of a disease, or to affect the structure of any function of the prevention of a disease, or to affect the structure of any function of the human body, but does not include intermediates used in the synthesis of human body, but does not include intermediates used in the synthesis of such ingredient.”such ingredient.”
4
5,000–10,000Screened
5,000–10,000Screened
250Enter Preclinical
Testing
250Enter Preclinical
Testing
5Enter
Clinical Testing
5Enter
Clinical Testing
1Approved by
the FDA
1Approved by
the FDA
16
14
12
10
8
6
4
2
0
Net Cost: $802 million invested over 15 years Source: DiMasi et al. 2003, Tufts
Years
Discovery: (2-10 years)
Phase I: 20-80 healthy volunteers to determine
safety & dosage
Phase III: 1000-5000 volunteers to monitor adverse reactions to
long-term use
Phase II: 100-300 volunteers to look for efficacy & side effects
FDA Review ApprovalAdditional
post-market testing
Preclinical: laboratory & animal tests
Compound Success Rates by Stage
R&D Is Risky & Costly
5
Choosing a Disease• Most research is carried Most research is carried
out on diseases which out on diseases which afflict “first world” afflict “first world” countries: (e.g. cancer, countries: (e.g. cancer, cardiovascular diseases, cardiovascular diseases, depression, diabetes, flu, depression, diabetes, flu, migraine, obesity).migraine, obesity).
6
Identifying a Drug Target• Drug Target = specific macromolecule, or Drug Target = specific macromolecule, or
biological system, which the drug will biological system, which the drug will interact with.interact with.
7
Proposing new drug (Drug Discovery)
Drug source and selection approachesDrug source and selection approaches• Irrational approachIrrational approach• Rational approachRational approach• Antisense ApproachAntisense Approach• RNAi ApproachRNAi Approach• BiologicsBiologics• Gene TherapyGene Therapy• ..• ..• .. O
HO
HN
HO
CH3
O
O
HN
O
CH3
O CH3
O
CH3
O
CH3O
HN
HO
CH3
codeineheroin
morphine
8
In silico methods
http://www.click2drug.org/
9
Choosing the Bioassay
• Definitions:Definitions:• In vitroIn vitro:: In an artificial environment, as in a test In an artificial environment, as in a test
tube or culture mediatube or culture media• In vivoIn vivo:: In the living body, referring to tests In the living body, referring to tests
conducted in living animalsconducted in living animals• Ex vivoEx vivo:: Usually refers to doing the test on a Usually refers to doing the test on a
tissue taken from a living organism.tissue taken from a living organism.
10
What is Pharmacology ?
PharmacologyPharmacology
Pharmacokinetics Pharmacodynamics
What the body does to drug What the drug does to body
ToxicologyToxicology, , carcinogenicity, mutagenicitycarcinogenicity, mutagenicityAnimal Tests, In Vitro Assays, and In Silico MethodsAnimal Tests, In Vitro Assays, and In Silico Methods
Formulations and Delivery SystemsFormulations and Delivery Systems
11
Pharmacokinetics and Pharmacodynamics
12
What the body does to the drug- Absorption- Distribution-Metabolism - Excretion
Pharmacokinetics
Bioavailablity <1Bioavailablity =1
13
Distribution
•Passive diffusion
•Facilitated diffusion
•Active transport
14
Drug Metabolism• Most metabolic products are Most metabolic products are less pharmacologically activeless pharmacologically active• Close relationshipClose relationship between the between the biotransformation of drugsbiotransformation of drugs
and and normal biochemical processesnormal biochemical processes occurring in the body: occurring in the body:• Metabolism of drugs involves many pathways associated with the Metabolism of drugs involves many pathways associated with the
synthesis of endogenous substrates such as steroid hormones, cholesterol synthesis of endogenous substrates such as steroid hormones, cholesterol
and bile acids and bile acids • Many of the enzymes involved in drug metabolism are principally Many of the enzymes involved in drug metabolism are principally
designed for the metabolism of endogenous compoundsdesigned for the metabolism of endogenous compounds• These enzymes metabolize drugs only because the These enzymes metabolize drugs only because the drugs resemble the drugs resemble the
natural compoundnatural compound
15
Phases of Drug Metabolism• Phase I ReactionsPhase I Reactions
• Convert parent compound into a more polar (=hydrophilic) metabolite by Convert parent compound into a more polar (=hydrophilic) metabolite by adding adding or unmasking functional groupsor unmasking functional groups (-OH, -SH, -NH (-OH, -SH, -NH22, -COOH, etc.), -COOH, etc.)
• Often these metabolites are inactiveOften these metabolites are inactive• May be sufficiently polar to be excreted readilyMay be sufficiently polar to be excreted readily
• Phase II ReactionsPhase II Reactions
• Conjugation with endogenous substrateConjugation with endogenous substrate to further increase aqueous solubility to further increase aqueous solubility• Conjugation with glucuronideConjugation with glucuronide, sulfate, acetate, amino acid, sulfate, acetate, amino acid
Liver is principal site of drug metabolism:Liver is principal site of drug metabolism:• Other sites include the gut, lungs, skin and kidneysOther sites include the gut, lungs, skin and kidneys• For orally administered compounds, there is theFor orally administered compounds, there is the
““First Pass Effect”First Pass Effect”• Intestinal metabolismIntestinal metabolism• Liver metabolismLiver metabolism• Enterohepatic recyclingEnterohepatic recycling• Gut microorganisms - glucuronidasesGut microorganisms - glucuronidases
16
Drug Metabolism - Phase I• Phase I ReactionsPhase I Reactions
• OxidationOxidation• ReductionReduction• Hydrolytic cleavageHydrolytic cleavage• Alkylation (Methylation)Alkylation (Methylation)• DealkylationDealkylation• Ring cyclizationRing cyclization• N-carboxylationN-carboxylation• DimerizationDimerization• TransamidationTransamidation• IsomerizationIsomerization• DecarboxylationDecarboxylation
17
Drug Metabolism - Phase II • Conjugation reactionsConjugation reactions
• GlucuronidationGlucuronidation by UDP-Glucuronosyltransferase: by UDP-Glucuronosyltransferase:
(on -OH, -COOH, -NH(on -OH, -COOH, -NH22, -SH groups), -SH groups)• SulfationSulfation by Sulfotransferase: by Sulfotransferase:
(on -NH2, -SO(on -NH2, -SO22NHNH22, -OH groups), -OH groups)• AcetylationAcetylation by acetyltransferase: by acetyltransferase:
(on -NH(on -NH22, -SO, -SO22NHNH22, -OH groups), -OH groups)• Amino acid conjugationAmino acid conjugation
(on -COOH groups)(on -COOH groups)• Glutathione conjugationGlutathione conjugation by Glutathione-S-transferase: by Glutathione-S-transferase:
(to epoxides or organic halides)(to epoxides or organic halides)• Fatty acid conjugationFatty acid conjugation
(on -OH groups)(on -OH groups)• Condensation reactionsCondensation reactions
18
Excretion
19
What the drug does to the body- Drug receptors- Effects of drug- Responses to drugs- Toxicity and adverse effects of drugs
Pharmacodynamics
Target validation• Microarray for disease target identifi cation• Radioligands• High throughput screening• Combinatorial chemistry• Structure – activity relationships: X - ray crystallography, nuclear magnetic resonance,
computational chemistry• Genomics and proteomics• Metabolomics• Systems biology• Nanotechnology• Bioinformatics: data mining• Recombinant DNA technologies
20
21
IND Review Process (when Preclinical research finished)
22
NDA Review Process
23
• To increase success To increase success • To increase bioavailabilityTo increase bioavailability• To pass liver metabolism “First pass To pass liver metabolism “First pass
effect” effect” • To increase Half LifeTo increase Half Life• To increase the target to non-target uptakeTo increase the target to non-target uptakeProdrug can be a choice
24
What is the Prodrug?• Prodrug - a pharmacologically inactive compound that is Prodrug - a pharmacologically inactive compound that is
converted to an active drug by a metabolic biotransformation converted to an active drug by a metabolic biotransformation (enzymatic or chemical hydrolysis)(enzymatic or chemical hydrolysis)
• Ideally,Ideally, conversion occurs as soon as the desired goal for conversion occurs as soon as the desired goal for designing the prodrug is achieved.designing the prodrug is achieved.
• Prodrugs currently constitute Prodrugs currently constitute 5%5% of known drugs and a larger percentage of of known drugs and a larger percentage of new drugsnew drugs
25
The barriers!!!
•Low oral absorption properties• Lack of site specificity• Chemical instability• Toxicity• Bad taste• Bad odour• Pain at application site
26
27
Why to use Prodrugs?
•Increased SolubilityImprove patient acceptability (decrease pain on injection)•improve chemical stability•minimize toxicity and side effects
•Improved Permeability and BioavailabilityAlter or improve absorption.
•Prolonged Half-LifeAlter biodistributionAlter metabolismeliminationTissue-Targeted Delivery
28
characteristics of prodrugs• It should not have intrinsic pharmacological It should not have intrinsic pharmacological
activity.activity.• The prodrug must be readily transported to The prodrug must be readily transported to
site of action.site of action.• The prodrug must be selectively cleaved to The prodrug must be selectively cleaved to
active drug utilizing specific enzymes.active drug utilizing specific enzymes.
29
30
31
Classification of Prodrugs
1- Carrier linked prodrug
2- Bioprecursor
32
2-Bioprecursor prodrugs
It does not contain a temporary linkage between the active drug It does not contain a temporary linkage between the active drug & a carrier moiety but designed from a molecular modification & a carrier moiety but designed from a molecular modification of the active principle itself.of the active principle itself.
It is a compound that is converted to active drug by a Metabolic It is a compound that is converted to active drug by a Metabolic biotransformation.biotransformation.
Types of activation-Types of activation- OxidaOxidation (most common method) tion (most common method) ReductionReduction Phosphorylation (For antiviral agents) Phosphorylation (For antiviral agents)
33
Oxidation Example –
Nabumetone, which is a Non-steroidal anti-inflammatory prodrug used in arthritis
CH3
O
CH3O
OH
CH3OO
series of oxidative
decaboxylation
Active form of the drug that inhibits Prostaglandin biosynthesis by cyclo-oxygenase
Nabumetone
34
1- Carrier linked prodrug
Contain a group that can be easily removed enzymatically to Contain a group that can be easily removed enzymatically to reveal the true drugsreveal the true drugs
Ideally the group removed is pharmacologicallyIdeally the group removed is pharmacologically
inactive and nontoxic while the connecting bond must be labile inactive and nontoxic while the connecting bond must be labile for efficient activation in vivofor efficient activation in vivo
Bipartite- Bipartite- Composed of one carrierComposed of one carrier group group attached to the drugsattached to the drugsTripartite- Tripartite- Carrier group is attached via Carrier group is attached via linker to druglinker to drugMutual ProdrugsMutual Prodrugs- - Two drugs linked Two drugs linked togethertogether
35
• Mutual prodrugMutual prodrug • In such type of prodrug two pharmacologically In such type of prodrug two pharmacologically
active agents are coupled to form a single active agents are coupled to form a single molecule which acts as carrier for others.molecule which acts as carrier for others.
• Eg.benorylate is a mutual prodrug of Aspirin Eg.benorylate is a mutual prodrug of Aspirin & Paracetamol.& Paracetamol.
C
O
O
NH C
O
CH3OCOCH3
COOH
OCOCH3
OH
NHCOCH3
+
prodrug
ParacetamolAsprin
Benorylate
36
Carrier linked prodrug(bi & tri partite)
• Targeting-ligand conjugated prodrugAntibody-drug conjugatePeptide–drug conjugate ...• Membrane transporter-associated prodrug • Polymeric prodrug PEG–drug conjugate HPMA–drug conjugate PLGA- –drug conjugate • Enzyme cleavable prodrugAntibody-directed enzyme prodrug therapy (ADEPT) Gene-directed enzyme prodrug therapy (GDEPT)
Directly or
by spacer conjugated
×
37
38
39
Prodrugs for Site Specificity (targeted therapy)
• Site specific delivery is a ultimate goal in all drug delivery research program, Site specific delivery is a ultimate goal in all drug delivery research program, where optimal therapeutic benefit of a drug is obtained & unwanted effect are where optimal therapeutic benefit of a drug is obtained & unwanted effect are minimized.minimized.
• It is desirable for It is desirable for highly toxic compoundhighly toxic compound such as employed in a cancer. such as employed in a cancer.• The main aim of Prodrug for Site Specificity is to achieve very precise and The main aim of Prodrug for Site Specificity is to achieve very precise and
direct effect at the target with minimal effect on rest of the body.direct effect at the target with minimal effect on rest of the body.• One important parameter in prodrugs for site specificity is the Drug One important parameter in prodrugs for site specificity is the Drug
therapeutic index.therapeutic index. A drug after its absorption into systemic circulation gets distributed A drug after its absorption into systemic circulation gets distributed into into
target as well as non-target site.target as well as non-target site. The distribution to non-targeted tissue may leads to undesirable toxic effect The distribution to non-targeted tissue may leads to undesirable toxic effect
and also insufficient concentration to the target site.and also insufficient concentration to the target site. If the target is too long and take more time for distribution the drug may get If the target is too long and take more time for distribution the drug may get
eliminated without reaching such a site.eliminated without reaching such a site. To minimize such a problems in a targeted drug delivery prodrug approach To minimize such a problems in a targeted drug delivery prodrug approach
has been used.has been used.
40
Novel prodrugs with modified properties has been designed which preferentially achieve higher concentration of biotransformed drug at the desired targeting sites such as-
Brain targeting
Kidney targeting
Liver targeting
Virus targeting
Tumor targeting
Lymphatic targeting
Colon targeting
41
Targeting to brain
In a brain targeting, delivery of drug is limited by Blood Brain Barrier In a brain targeting, delivery of drug is limited by Blood Brain Barrier (BBB).(BBB).
The Blood Brain Barrier can allows The Blood Brain Barrier can allows only small and lipid solubleonly small and lipid soluble molecules, molecules,
which can diffuse the BBB from systemic circulation.which can diffuse the BBB from systemic circulation.
But the larger, more water soluble and ionic molecules But the larger, more water soluble and ionic molecules do notdo not readily cross readily cross BBB.BBB.
The BBB allows only lipophilic molecules to enter brain, on this basis The BBB allows only lipophilic molecules to enter brain, on this basis
Bodor and Co-workers (1981) developedBodor and Co-workers (1981) developed Dihydropyridine-pyridiniumDihydropyridine-pyridinium type redox system for Brain specific sustain drug delivery. type redox system for Brain specific sustain drug delivery.
42
43
Targeting to Tumor
Tumor cells contains a higher concentration of enzyme phosphates, amides than do normal cells.
Because of higher growth rates associated with tumor cells. For tumor drug delivery firstly studied prodrug activating
enzyme (extracellular or intracellular) For selective activation of prodrugs in tumor cells
Two steps: Selecting a specific linker based on tumor cell specific enzyme. Incorporate a prodrug-activating enzyme into a target tumor
cell.
44
Criteria for Success With Enzyme-Prodrug Therapies
The prodrug-activating enzyme is either nonhuman or a human protein.
It should be a good substrate for the incorporated enzyme but not be activated by endogenous enzyme outside tumor cell.
Prodrug must be able to cross tumor cell membranes. Prodrug have low cytotoxicity and drug have high
cytotoxicity. The half-life of the active drug is long enough for bystander
killing effect but short enough to avoid leaking out of tumor cells.
45
Antibody targeted drugs as cancertherapeutics
NATURE REVIEWS | DRUG DISCOVERY VOLUME 5 | FEBRUARY 2006 | 147
46
Antibody targeted drugs as cancer therapeutics-continued
47
pH-labile Hydrazone linkers
48
49
PSA labile spacer
50
51
Antibody-Directed Enzyme Prodrug Therapy (ADEPT)
Administration of
Antibody-enzyme conjugate
Administration of prodrug
Prodrug
Enzyme
Drug
Tumor cell
An approach for site-specific delivery of cancer drugs
52
An antibody-enzyme conjugate is administered which binds to the surface of the tumor cells.
The antibody used has been targeted for the particular tumor cell.
After the antibody-enzyme has localized within the tumor cell and the excess conjugate is cleared from the blood and normal tissues get enough time to clear.
After the prodrug is administered, The Ab-E conjugated at the tumor cell surface catalyzes the conversion of the prodrug to the drug when it reaches the tumor cell.
53
Example:
Delivery of Nitrogen mustard as a Glutamic acid conjugate, after administration of humanized monoclonal antibody conjugated to the bacterial enzyme carboxypeptidase G2.
Prodrug-activating enzyme in ADEPT is a bacterial enzyme.
IN
I
O NH
O
C O 2 H
C O 2 H
IN
O H
I
carboxypeptidaseG2Carboxypeptidase G2
Nitrogen mustard as a Glutamic acid conjugate Activated Nitrogen mustard
L-Glu + CO2+
54
Gene-Directed Enzyme Prodrug Therapy (GDEPT)
• An inactive prodrug can be activated to release of An inactive prodrug can be activated to release of cytotoxic drug by an enzyme that has been delivered via cytotoxic drug by an enzyme that has been delivered via gene to the tumor cell.gene to the tumor cell.
A gene encoding prodrug-activating enzyme is integrated A gene encoding prodrug-activating enzyme is integrated into a genome of targeted tumor cells or viral vector under into a genome of targeted tumor cells or viral vector under the control of tumor-selective promoters.the control of tumor-selective promoters.
These cells, then express the enzyme that activates the These cells, then express the enzyme that activates the prodrug.prodrug.
55
• Pro-prodrug (Double prodrugs)Pro-prodrug (Double prodrugs)• Here the prodrug is further derivatised a Here the prodrug is further derivatised a
fashion such that two steps as enzymatically or fashion such that two steps as enzymatically or chemically conversion lead to release active chemically conversion lead to release active drug.drug.
CH C
NH2 O
NH2S
CH3
CH3
C
O
O CH2 O C C
CH3
CH3
CH3O
proprodrugenzymatic clevage
S
CH3
CH3
CO
OCH2OH
H
O
PRODRUG
N
S
CH3
CH3
O
H
Ampicillin ACTIVE
56
Triple prodrug
Double prodrugprodrug
57
Conclusion• Knowing “what happened for drugs in the Knowing “what happened for drugs in the
body and how drugs act” can help a chemist body and how drugs act” can help a chemist to design to more effective drugs to design to more effective drugs
• Prodrug strategy increases the success of Prodrug strategy increases the success of Drug Discovery and Development process.Drug Discovery and Development process.
58
References
• Adv. Drug Deliv. Rev. (2011),Adv. Drug Deliv. Rev. (2011),• Advanced Drug Delivery Reviews 63 (2011) 3–23Advanced Drug Delivery Reviews 63 (2011) 3–23• drugs From Discovery to Approval, 2009drugs From Discovery to Approval, 2009• Evaluation of Drug Candidates for Preclinical Development, Evaluation of Drug Candidates for Preclinical Development,
2010 2010 • NNature reviewsature reviews,,drug discoverydrug discovery,, volume 7 volume 7 ,,20082008, , 255255• The AAPS JournalThe AAPS Journal, vol 10, no1,2008,92, vol 10, no1,2008,92• Current Pharmaceutical Design, 2009, 15, 2236-2250Current Pharmaceutical Design, 2009, 15, 2236-2250• Prog. Polym. Sci. 32 (2007) 933–961Prog. Polym. Sci. 32 (2007) 933–961• Nature Reviews,drug discovery, volume 5 ,2006,147Nature Reviews,drug discovery, volume 5 ,2006,147• Bioorg Med Chem. 2008 March 15; 16(6): 2764–2768.Bioorg Med Chem. 2008 March 15; 16(6): 2764–2768.• Asian J. Research Chem. 2(2): April.-June, 2009Asian J. Research Chem. 2(2): April.-June, 2009• Advanced Drug Delivery Reviews 26 (1997) 151–172Advanced Drug Delivery Reviews 26 (1997) 151–172• Pharmacol Rev 56:53–102, 2004Pharmacol Rev 56:53–102, 2004
59
??
? ?? ?
? ? ?? ? ?
60
Target Validation
61
62